FLUOXETINE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for fluoxetine hydrochloride and what is the scope of patent protection?

Fluoxetine hydrochloride is the generic ingredient in eight branded drugs marketed by Barr, Dr Reddys Labs Ltd, Lilly, Sun Pharm Industries, Watson Labs, Accord Hlthcare, Alembic Pharms Ltd, Ani Pharms, Apnar Pharma Lp, Aurobindo Pharma, Cadila Pharms Ltd, Carlsbad, Chartwell Rx, Cr Double Crane, Heritage, Ivax Sub Teva Pharms, Landela Pharm, Marksans Pharma, Micro Labs, Natco Pharma Usa, Pharmobedient, Regcon Holdings, Sandoz, Sciegen Pharms, Specgx Llc, Strides Pharma Intl, Sun Pharm Inds Ltd, Teva, Teva Pharms Usa, Eli Lilly And Co, Actavis Mid Atlantic, Bajaj, Chartwell Molecular, Lannett Co Inc, Novitium Pharma, Pharm Assoc, Pharmobedient Cnsltg, Solis Pharms, Upsher Smith Labs, Alembic, Aurobindo Pharma Ltd, Dr Reddys, Fosun Pharma, G And W Labs Inc, Inventia Hlthcare, Lupin Ltd, Ph Health, Rising, Somerset Theraps Llc, Strides Pharma, Torrent, Twi Pharms, Apil, Epic Pharma Llc, and Teva Pharms, and is included in eighty NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for fluoxetine hydrochloride. Sixty-two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for FLUOXETINE HYDROCHLORIDE

US Patents:	0
Tradenames:	8
Applicants:	55
NDAs:	80
Drug Master File Entries:	20
Finished Product Suppliers / Packagers:	62
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	318
Patent Applications:	7,646
What excipients (inactive ingredients) are in FLUOXETINE HYDROCHLORIDE?	FLUOXETINE HYDROCHLORIDE excipients list
DailyMed Link:	FLUOXETINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for FLUOXETINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Minnesota	PHASE2
Tanta University	PHASE1
First Affiliated Hospital of Chongqing Medical University	PHASE2

See all FLUOXETINE HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for FLUOXETINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 40MG BASE	CAPSULE;ORAL
		EQ 20MG BASE	CAPSULE;ORAL
		EQ 10MG BASE	CAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for FLUOXETINE HYDROCHLORIDE

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for FLUOXETINE HYDROCHLORIDE

Antidepressive Agents, Second-Generation

Cytochrome P-450 CYP2D6 Inhibitors

Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for FLUOXETINE HYDROCHLORIDE

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for FLUOXETINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apil	SARAFEM	fluoxetine hydrochloride	TABLET;ORAL	021860-002	May 19, 2006		DISCN	Yes	No
Pharmobedient	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	CAPSULE;ORAL	075577-002	Jan 29, 2002		DISCN	No	No
Strides Pharma	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	TABLET;ORAL	212684-001	Apr 5, 2024	AB	RX	No	No
Strides Pharma	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	TABLET;ORAL	212683-001	Sep 13, 2024	AB	RX	No	No
Teva Pharms Usa	FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride	TABLET;ORAL	211051-001	Dec 3, 2018		DISCN	No	No
Sun Pharm Industries	FLUOXETINE	fluoxetine hydrochloride	CAPSULE;ORAL	075787-002	Jan 29, 2002		DISCN	No	No
Teva Pharms	OLANZAPINE AND FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	077528-002	Jun 19, 2012	AB	RX	No	No

Expired US Patents for FLUOXETINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eli Lilly And Co	SARAFEM	fluoxetine hydrochloride	CAPSULE;ORAL	018936-007	Jul 6, 2000	5,114,976*PED
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-001	Dec 29, 1987	4,018,895
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-001	Dec 29, 1987	4,329,356
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-003	Jun 15, 1999	6,960,577
Lilly	PROZAC WEEKLY	fluoxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021235-001	Feb 26, 2001	5,910,319*PED
Eli Lilly And Co	PROZAC	fluoxetine hydrochloride	CAPSULE;ORAL	018936-006	Dec 23, 1992	4,194,009
Lilly	PROZAC	fluoxetine hydrochloride	TABLET;ORAL	020974-002	Mar 9, 1999	4,314,081*PED

Market Dynamics and Financial Trajectory for Fluoxetine Hydrochloride

Last updated: April 1, 2026

What Is the Market Size and Growth Outlook for Fluoxetine Hydrochloride?

Fluoxetine hydrochloride, marketed under brand names like Prozac, is a selective serotonin reuptake inhibitor (SSRI) approved by the FDA in 1987 for depression, obsessive-compulsive disorder, bulimia nervosa, and panic disorder. The global antidepressant market, dominated by fluoxetine, was valued at approximately $15 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% to 4.0% through 2030.

While precise revenue figures for fluoxetine alone are proprietary, the drug accounts for roughly 20-25% of the antidepressant segment, translating into annual sales estimated at $3-$4 billion worldwide. Growth is driven by increasing prevalence of depression, expanding approval for off-label uses, and approvals in emerging markets.

How Does Patent Status Influence Market Dynamics?

Fluoxetine was initially protected under patent until 2001 in the U.S. and 1994 in Europe. Since patent expiry, the drug has faced a surge in generic competition, leading to significant price erosion.

Patent Expiry Year	Region	Patent Status	Market Impact
2001	U.S.	Patent expired	Entry of generics, price decline
1994	Europe	Patent expired	Similar generic influx

Generic versions are up to 80-90% cheaper than branded formulations, which has driven volume growth but compressed profit margins for originators.

What Are the Key Competitive Factors?

• Pricing: Generic competition drives prices down globally.
• Formulation: Extended-release formulations and combination therapies are emerging segments.
• Regulatory Approvals: Off-label indications and new formulations require ongoing regulatory submissions.
• Market Penetration: Regions such as Asia-Pacific show high growth potential due to increasing mental health awareness and healthcare access, despite the prevalence of generics.

What Are the Trends Shaping Future Distribution and Usage?

• Off-label Use Expansion: Use for conditions like premenstrual dysphoric disorder and certain anxiety disorders increases volume.
• Generic Market Penetration: Continues to suppress prices but expands overall sales volume.
• Regulatory Shifts: Consideration of biosimilars and reformulation approvals could alter competitive dynamics.
• Emerging Markets: Rapid growth in China, India, and Latin America with favorable healthcare infrastructure expansion.

What Is the Financial Outlook for Manufacturers?

Profitability depends heavily on patent status and market share:

Period	Revenue Trends	Profitability Impact
Pre-2001	High margins, brand dominance	High profit margins, limited to few firms
Post-2001	Price erosion due to generics	Margins decline, sales volume increases
2023–2030	Volume-driven, potential new formulations	Margins vary; innovation needed to sustain sales

Branded companies like Eli Lilly (original patent holder) have transitioned to biosimilars or diversified portfolios. Generic manufacturers (e.g., Teva, Sandoz) benefit from high-volume low-margin models.

Are There Innovations or Patents in Development?

Current innovation involves:

• Extended-release and combination formulations.
• Digital health integration for monitoring adherence.
• New indications supported by clinical trials, which could open secondary markets.

Patent filings target formulations and use claims extending life cycles of proprietary versions, but generic versions dominate sales due to patent expirations.

What Are the Regulatory and Market Entry Barriers?

• Regulatory Approvals: New formulations and indications require extensive clinical validation.
• Patent Litigation: Original patent holders have historically engaged in litigation to delay generic entry.
• Pricing Regulations: Price controls in Europe and other regions can influence sales margins.

Summary of Competitive Environment

Player Type	Market Share (est.)	Revenue Contribution	Strategic Focus
Brand manufacturers	20-30%	$1-$1.2 billion	Innovation, formulations, patent defenses
Generics manufacturers	70-80%	$2.8-$3.2 billion	Cost leadership, market penetration

Key Takeaways

• The patent expiration in early 2000s accelerated generic entry, compressing margins.
• The global antidepressant market's growth sustains high volume sales despite falling prices.
• Innovation focuses on formulations and expanding indications.
• Emerging markets exhibit rapid growth aligning with increased healthcare infrastructure.
• Regulatory environments and patent protections will continue to influence competitive dynamics.

FAQs

1. What factors influence the price decline of fluoxetine post-patent expiry?
   Entry of low-cost generics and increased competition drive prices down, sometimes up to 90% below branded prices.

2. Which regions offer the best growth opportunities for fluoxetine?
   Asia-Pacific and Latin America show increasing adoption driven by mental health awareness and expanding healthcare coverage.

3. Are there significant patent filings currently for fluoxetine?
   Limited patents are active, mostly for new formulations or specific indications. Original patents are expired.

4. How do regulatory changes impact the future of fluoxetine sales?
   Stringent approval processes for new indications or formulations can delay new product launches. Conversely, supportive policies may enable expansions.

5. What is the primary driver for sustained revenue in the face of generic competition?
   Ongoing volume growth, expansion into new markets, and development of novel formulations or combination therapies.

---

References

[1] Allied Market Research. (2022). Antidepressants Market. Market Research Future.